Summary
Healthcare automation startup Forus has raised $150 million in a Series C funding round, tripling its valuation to $3 billion just months after its previous fundraise. Bloomberg Tech’s Riley Griffin sits down with Forus CEO Sahir Jaggi to discuss the company’s rapid growth and what the new capital enables.
Forus has built an AI platform that helps patients navigate the complex web of insurance coverage, affordability programs, and supply chain logistics required to access specialty medications — conditions like autoimmune diseases, cancers, and neurological disorders where one in three patients never receives their first dose. The platform is already active across all 50 states, reaching 85% of U.S. ZIP codes, and is used by thousands of providers daily. The fresh capital will allow Forus to expand from its initial focus on dermatology, gastroenterology, and rheumatology into oncology, neurology, and beyond.
Jaggi also addresses the trust question head-on: Forus is funded by pharmaceutical companies, yet positions itself as a patient advocate. He argues that patients with chronic conditions are often the most eager for pharma involvement because they need these therapies to work — and that simplifying access is itself the value proposition, regardless of who pays for it.
📺 Source: Bloomberg Tech · Published September 08, 2026
🏷️ Format: Interview
